General Atlantic’s Immunocore IMCR Stock Holding History

General Atlantic’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,261,684	Closed	-$37.4M	–	16
2025 Q1	$37.4M	Hold	1,261,684	–	–	1.26%	10
2024 Q4	$37.2M	Hold	1,261,684	–	–	1.32%	10
2024 Q3	$39.3M	Hold	1,261,684	–	–	1.12%	13
2024 Q2	$42.8M	Sell	1,261,684 -245,000	-16%	-$12.5M	1.34%	11
2024 Q1	$97.9M	Buy	1,506,684 +556,684	+59%	+$38.2M	2.27%	11
2023 Q4	$64.9M	Hold	950,000	–	–	0.93%	13
2023 Q3	$49.3M	Hold	950,000	–	–	0.76%	19
2023 Q2	$57M	Hold	950,000	–	–	0.9%	17
2023 Q1	$47M	Hold	950,000	–	–	0.55%	18
2022 Q4	$54.2M	Hold	950,000	–	–	0.72%	18
2022 Q3	$44.6M	Hold	950,000	–	–	0.53%	18
2022 Q2	$35.4M	Hold	950,000	–	–	0.46%	19
2022 Q1	$28.4M	Hold	950,000	–	–	0.26%	22
2021 Q4	$32.5M	Hold	950,000	–	–	0.25%	22
2021 Q3	$35.2M	Hold	950,000	–	–	0.21%	19
2021 Q2	$37.1M	Hold	950,000	–	–	0.26%	13
2021 Q1	$40.4M	Buy	+950,000	New	+$42.3M	0.47%	9

Other funds holding IMCR

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

General Atlantic's IMCR Position: Q2 2025 in Review

General Atlantic sold out of Immunocore (IMCR) in Q2 2025, closing a stake of 1,261,684 shares — an estimated $37.4M sold.

General Atlantic first reported a position in IMCR in Q1 2021 and held it in 17 quarters. The position peaked at $97.9M in Q1 2024. 133 funds tracked by Wall St. Rank hold IMCR as of Q2 2025.

General Atlantic reported no remaining Immunocore position as of Q2 2025 after selling out during the quarter.
General Atlantic sold 1,261,684 Immunocore shares in Q2 2025, an estimated $37.4M.
General Atlantic first reported a position in Immunocore in Q1 2021 and held it in 17 quarters.
General Atlantic's Immunocore position peaked at $97.9M in Q1 2024.
133 funds tracked by Wall St. Rank held Immunocore as of Q2 2025.

Based on General Atlantic's 13F filing for Q2 2025, filed 14 Aug 2025.